Allogene Therapeutics Inc. Insider Trading

ALLO

Last 12 months

Insiders sold 669K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in May 2024.

Net open-market

−669K

0 buys · 15 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

May 2024

May 16, 2024

Get an email when ALLO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 21	Geoffrey M. Parker Chief Financial Officer	SoldNo plan	36,342	$1.34	49K	3.4%	Form 4
Aug 21	Earl Martin Douglas SVP, General Counsel	SoldNo plan	29,697	$2.12	63K	5.7%	Form 4
Apr 21	Annie Yoshiyama SVP, Finance	SoldNo plan	9,586	$2.31	22K	7.1%	Form 4
Mar 31	Benjamin Machinas Beneski SVP, Chief Technical Officer	SoldNo plan	2,867	$2.50	7K	1.4%	Form 4
Mar 16	Benjamin Machinas Beneski SVP, Chief Technical Officer	SoldNo plan	4,835	$2.47	12K	2.4%	Form 4
Mar 16	David D Chang President and CEO	SoldNo plan	47,763	$2.47	118K	0.8%	Form 4
Mar 2	Benjamin Machinas Beneski SVP, Chief Technical Officer	SoldNo plan	7,132	$2.60	19K	3.4%	Form 4
Feb 2	Benjamin Machinas Beneski SVP, Chief Technical Officer	SoldNo plan	7,549	$1.73	13K	3.5%	Form 4
Feb 2	David D Chang President and CEO	SoldNo plan	95,269	$1.80	171K	1.6%	Form 4
Feb 2	Geoffrey M. Parker Chief Financial Officer	SoldNo plan	24,001	$1.76	42K	1.9%	Form 4
Feb 2	Annie Yoshiyama SVP, Finance	SoldNo plan	4,167	$1.72	7K	3.1%	Form 4
Feb 2	Zachary Roberts EVP of R&D	SoldNo plan	35,700	$1.77	63K	5.8%	Form 4
Feb 2	Earl Martin Douglas SVP, General Counsel	SoldNo plan	22,900	$1.76	40K	3.9%	Form 4
Jan 21	Zachary Roberts EVP of R&D	SoldNo plan	26,269	$1.56	41K	4.1%	Form 4
Nov 17, 2025	Benjamin Machinas Beneski SVP, Chief Technical Officer	SoldNo plan	786	$1.22	$959	0.4%	Form 4
Oct 21, 2025	Geoffrey M. Parker Chief Financial Officer	SoldNo plan	36,744	$1.26	46K	2.8%	Form 4
Jun 10, 2025	Deborah M. Messemer Director	Sold10b5-1 plan	36,885	$1.42	52K	26%	Form 4
Apr 21, 2025	Annie Yoshiyama SVP, Finance	SoldNo plan	9,601	$1.41	14K	6.8%	Form 4
Mar 14, 2025	David D Chang President and CEO	SoldNo plan	46,668	$1.96	91K	0.8%	Form 4
Mar 14, 2025	Benjamin Machinas Beneski SVP, Chief Technical Officer	SoldNo plan	5,488	$1.98	11K	2.5%	Form 4
Feb 18, 2025	Deborah M. Messemer Director	Sold10b5-1 plan	13,313	$2.43	32K	8.4%	Form 4
Feb 3, 2025	Earl Martin Douglas SVP, General Counsel	SoldNo plan	6,404	$1.71	11K	1.1%	Form 4
Feb 3, 2025	Geoffrey M. Parker Chief Financial Officer	SoldNo plan	4,361	$1.73	8K	0.3%	Form 4
Feb 3, 2025	Timothy L. Moore Chief Technical Officer	SoldNo plan	14,746	$1.71	25K	5.6%	Form 4
Feb 3, 2025	David D Chang President and CEO	SoldNo plan	46,003	$1.68	77K	0.7%	Form 4
Feb 3, 2025	Zachary Roberts EVP of R&D	SoldNo plan	18,832	$1.70	32K	2.8%	Form 4
Jan 21, 2025	Zachary Roberts EVP of R&D	SoldNo plan	27,199	$1.78	48K	5.3%	Form 4
Dec 9, 2024	Deborah M. Messemer Director	Sold10b5-1 plan	9,136	$2.18	20K	5.5%	Form 4
Dec 5, 2024	Franz B Humer Director	SoldNo plan	9,221	$2.16	20K	2.9%	Form 4

Oct 21No plan
Geoffrey M. Parker
Chief Financial Officer · sold 36,342 at $1.34
49K
3.4% of stake
Aug 21No plan
Earl Martin Douglas
SVP, General Counsel · sold 29,697 at $2.12
63K
5.7% of stake
Apr 21No plan
Annie Yoshiyama
SVP, Finance · sold 9,586 at $2.31
22K
7.1% of stake
Mar 31No plan
Benjamin Machinas Beneski
SVP, Chief Technical Officer · sold 2,867 at $2.50
7K
1.4% of stake
Mar 16No plan
Benjamin Machinas Beneski
SVP, Chief Technical Officer · sold 4,835 at $2.47
12K
2.4% of stake
Mar 16No plan
David D Chang
President and CEO · sold 47,763 at $2.47
118K
0.8% of stake
Mar 2No plan
Benjamin Machinas Beneski
SVP, Chief Technical Officer · sold 7,132 at $2.60
19K
3.4% of stake
Feb 2No plan
Benjamin Machinas Beneski
SVP, Chief Technical Officer · sold 7,549 at $1.73
13K
3.5% of stake
Feb 2No plan
David D Chang
President and CEO · sold 95,269 at $1.80
171K
1.6% of stake
Feb 2No plan
Geoffrey M. Parker
Chief Financial Officer · sold 24,001 at $1.76
42K
1.9% of stake
Feb 2No plan
Annie Yoshiyama
SVP, Finance · sold 4,167 at $1.72
7K
3.1% of stake
Feb 2No plan
Zachary Roberts
EVP of R&D · sold 35,700 at $1.77
63K
5.8% of stake
Feb 2No plan
Earl Martin Douglas
SVP, General Counsel · sold 22,900 at $1.76
40K
3.9% of stake
Jan 21No plan
Zachary Roberts
EVP of R&D · sold 26,269 at $1.56
41K
4.1% of stake
Nov 17, 2025No plan
Benjamin Machinas Beneski
SVP, Chief Technical Officer · sold 786 at $1.22
$959
0.4% of stake
Oct 21, 2025No plan
Geoffrey M. Parker
Chief Financial Officer · sold 36,744 at $1.26
46K
2.8% of stake
Jun 10, 202510b5-1 plan
Deborah M. Messemer
Director · sold 36,885 at $1.42
52K
26% of stake
Apr 21, 2025No plan
Annie Yoshiyama
SVP, Finance · sold 9,601 at $1.41
14K
6.8% of stake
Mar 14, 2025No plan
David D Chang
President and CEO · sold 46,668 at $1.96
91K
0.8% of stake
Mar 14, 2025No plan
Benjamin Machinas Beneski
SVP, Chief Technical Officer · sold 5,488 at $1.98
11K
2.5% of stake
Feb 18, 202510b5-1 plan
Deborah M. Messemer
Director · sold 13,313 at $2.43
32K
8.4% of stake
Feb 3, 2025No plan
Earl Martin Douglas
SVP, General Counsel · sold 6,404 at $1.71
11K
1.1% of stake
Feb 3, 2025No plan
Geoffrey M. Parker
Chief Financial Officer · sold 4,361 at $1.73
8K
0.3% of stake
Feb 3, 2025No plan
Timothy L. Moore
Chief Technical Officer · sold 14,746 at $1.71
25K
5.6% of stake
Feb 3, 2025No plan
David D Chang
President and CEO · sold 46,003 at $1.68
77K
0.7% of stake
Feb 3, 2025No plan
Zachary Roberts
EVP of R&D · sold 18,832 at $1.70
32K
2.8% of stake
Jan 21, 2025No plan
Zachary Roberts
EVP of R&D · sold 27,199 at $1.78
48K
5.3% of stake
Dec 9, 202410b5-1 plan
Deborah M. Messemer
Director · sold 9,136 at $2.18
20K
5.5% of stake
Dec 5, 2024No plan
Franz B Humer
Director · sold 9,221 at $2.16
20K
2.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ALLO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ALLO

CompareIntrinsic value

ATRAAtara Biotherapeutics, Inc.

$8.37+2.07%15

ELOXEloxx Pharmaceuticals, Inc.

$12.74-1.39%20

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

AUTLAutolus Therapeutics plc

$1.38-2.83%40

TSHATaysha Gene Therapies Inc.

$4.36+6.60%40

CRDFCardiff Oncology Inc.

$0.87+1.03%36

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

PROKProKidney Corp

$1.12+4.67%10

Held by ETFs

ALLO is in 22 US ETFs. The largest of them, with ALLO's weight in each:

Spot a number that looks wrong? Check it in ALLO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALLO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.